罗莫索单抗在FRAME试验中欧洲患者的疗效与安全性
本文为FRAME试验的事后分析,评估罗莫索单抗在欧洲绝经后骨质疏松症患者中的疗效与安全性。欧洲患者占FRAME总人群的41.96%(3013/7180),随机接受罗莫索单抗210 mg或安慰剂每月一次治疗12个月,随后开放标签地舒单抗60 mg每6个月一次至36个月。罗莫索单抗治疗12个月显著降低非椎体骨折、临床骨折、新发椎体骨折和主要骨质疏松性骨折风险,并在转换为地舒单抗后持续至36个月,同时骨密度大幅增加,不良事件两组平衡。
要点
- 欧洲患者占FRAME试验的41.96%(3013/7180),罗莫索单抗组1494例,安慰剂组1519例。
- 治疗12个月,罗莫索单抗较安慰剂显著降低非椎体骨折(1.4% vs 3.0%,p=0.004)、临床骨折(1.4% vs 3.6%,p<0.001)、新发椎体骨折(0.4% vs 2.1%,p<0.001)和主要骨质疏松性骨折(0.9% vs 2.8%,p<0.001)风险。
- 髋部骨折在12个月时数值上降低(0.2% vs 0.6%,p=0.092),未达统计学显著;不良事件两组平衡。
核心结论
- 在欧洲FRAME患者中,罗莫索单抗早期且持续降低所有主要骨折类别风险,并伴随骨密度大幅增加,该增加在转换为地舒单抗后继续。
研究设计与样本
- FRAME(NCT01575834)为多国3期随机对照试验,患者按1:1随机接受罗莫索单抗210 mg或安慰剂每月一次治疗12个月,随后开放标签地舒单抗60 mg每6个月一次至36个月,包括12个月延伸研究。
- 本分析为事后分析,报告入组FRAME的欧洲患者的主要骨折结局发生率、骨密度自基线变化及安全性;欧洲患者共3013/7180例(41.96%),其中罗莫索单抗组1494例,安慰剂组1519例。
主要发现
- 治疗12个月,罗莫索单抗组较安慰剂组非椎体骨折发生率为1.4% vs 3.0%(p=0.004)。
- 治疗12个月,罗莫索单抗组较安慰剂组临床骨折发生率为1.4% vs 3.6%(p<0.001)。
- 治疗12个月,罗莫索单抗组较安慰剂组新发椎体骨折发生率为0.4% vs 2.1%(p<0.001)。
- 治疗12个月,罗莫索单抗组较安慰剂组主要骨质疏松性骨折发生率为0.9% vs 2.8%(p<0.001),结果持续至转换为地舒单抗后的36个月。
- 治疗12个月,髋部骨折在罗莫索单抗组数值上低于安慰剂组(0.2% vs 0.6%,p=0.092);罗莫索单抗组骨密度较安慰剂组增加,且两组患者在转换为地舒单抗后至36个月骨密度均进一步增加;不良事件两组平衡。
关键数值与推荐
- 罗莫索单抗用法为210 mg每月一次皮下注射,治疗12个月。
- 地舒单抗用法为60 mg每6个月一次,开放标签,至36个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: In this post hoc analysis, we assessed romosozumab efficacy and safety in European patients enrolled in FRAME. Romosozumab treatment through 12 months, followed by denosumab for a further 24 months, resulted in early and sustained risk reduction for major fracture categories, associated with large gains in bone mineral density. INTRODUCTION: In the multinational FRAME phase 3 trial of romosozumab in postmenopausal women with osteoporosis, marked differences between clinical and non-vertebral fracture outcomes were observed among patients from Central and Southern America versus rest of world. This post hoc analysis assessed romosozumab efficacy and safety in European patients enrolled in the FRAME trial and extension study. METHODS: In FRAME (NCT01575834), patients were randomised 1:1 to romosozumab 210 mg or placebo monthly (QM) for 12 months, followed by open-label denosumab 60 mg Q6M to month 36, including a 12-month extension study. We report incidence of major fracture outcomes, bone mineral density (BMD) change from baseline and safety for European patients enrolled in FRAME. RESULTS: In FRAME, 3013/7180 (41.96%) patients were European; 1494 received romosozumab and 1519 received placebo. Through 12 months, romosozumab reduced fracture risk versus placebo for non-vertebral fracture (1.4% versus 3.0%; p = 0.004), clinical fracture (1.4% versus 3.6%; p < 0.001), new vertebral fracture (0.4% versus 2.1%; p < 0.001) and major osteoporotic fracture (0.9% versus 2.8%; p < 0.001), with results sustained through 36 months following transition to denosumab. Hip fractures were numerically reduced with romosozumab at month 12 (0.2% versus 0.6%; p = 0.092). Romosozumab increased BMD versus placebo at month 12; all patients in the romosozumab and placebo groups experienced further increases by month 36 after transition to denosumab. Adverse events were balanced between groups. CONCLUSIONS: Among European patients in FRAME, romosozumab resulted in early and sustained risk reduction for all major fracture categories, associated with large BMD gains that continued after transition to denosumab.
引用
- Langdahl B, Hofbauer LC, Ferrari S, et al. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial. Osteoporos Int. 2022. PMID: 36173415. doi:10.1007/s00198-022-06544-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。